ADAGENE INC. SP.ADR (F:978) — Market Cap & Net Worth
Market Cap & Net Worth: ADAGENE INC. SP.ADR (978)
ADAGENE INC. SP.ADR (F:978) has a market capitalization of $237.92 Million (€203.50 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #15947 globally and #1533 in its home market, demonstrating a -2.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADAGENE INC. SP.ADR's stock price €3.08 by its total outstanding shares 66072594 (66.07 Million). Review ADAGENE INC. SP.ADR (978) financial obligations to assess the company's total debt and financial obligations.
ADAGENE INC. SP.ADR Market Cap History: 2021 to 2026
ADAGENE INC. SP.ADR's market capitalization history from 2021 to 2026. Data shows change from $834.25 Million to $230.19 Million (-30.38% CAGR).
ADAGENE INC. SP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADAGENE INC. SP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.80x
ADAGENE INC. SP.ADR's market cap is 14.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $834.25 Million | $10.18 Million | -$73.18 Million | 81.99x | N/A |
| 2022 | $83.43 Million | $9.29 Million | -$79.97 Million | 8.98x | N/A |
| 2023 | $115.10 Million | $18.11 Million | -$18.95 Million | 6.35x | N/A |
| 2024 | $139.81 Million | $103.20K | -$33.42 Million | 1354.74x | N/A |
| 2025 | $113.55 Million | $7.67 Million | -$17.61 Million | 14.80x | N/A |
Competitor Companies of 978 by Market Capitalization
Companies near ADAGENE INC. SP.ADR in the global market cap rankings as of June 19, 2026.
Key companies related to ADAGENE INC. SP.ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
ADAGENE INC. SP.ADR Historical Marketcap From 2021 to 2026
Between 2021 and today, ADAGENE INC. SP.ADR's market cap moved from $834.25 Million to $ 230.19 Million, with a yearly change of -30.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €230.19 Million | +102.72% |
| 2025 | €113.55 Million | -18.78% |
| 2024 | €139.81 Million | +21.48% |
| 2023 | €115.10 Million | +37.96% |
| 2022 | €83.43 Million | -90.00% |
| 2021 | €834.25 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ADAGENE INC. SP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $237.92 Million USD |
| MoneyControl | $237.92 Million USD |
| MarketWatch | $237.92 Million USD |
| marketcap.company | $237.92 Million USD |
| Reuters | $237.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more